

Freedom of Information Request: Our Reference CTHB_226_17

You asked:

Within your trust how many patients have been treated, in the past 6 months January to June, 2017 by diagnosed eye condition. Of these patients how many are new to treatment [they have not previously received an injection /implant]?

	Total Patients	New Patients	Lucentis (ranibizumab) Patients	Lucentis (ranibizumab) NEW Patients	Eylea (aflibercept) Patients	Eylea (aflibercept) NEW Patients
Total						
Wet Age Related Macular Degeneration (wAMD)						
Other conditions (DMO, RVO or mCNV)						

If you do not have full records an estimate would be helpful.

Our response:

In response to your recent request the table you have provided below has been populated with the number of injections administered during the period of January 2017 and June 2017, by medicine and by diagnosed eye condition. Unfortunately, due to the way our data is captured we are unable to provide this information by number of patients treated. We are also unable to confirm if all the new injections meet the 'New' criteria you have specified above i.e. a patient may have started treatment with Lucentis but then switched to Eylea or vice versa.

	Total Injections	New Injections	Lucentis (ranibizumab) Total Injections	Lucentis (ranibizumab) New Injections	Eylea (aflibercept) Total Injections	Eylea (aflibercept) New Injections
Total	1755	202	1062	103	693	99
Wet Age Related Macular Degeneration (wAMD)	1218	124	671	68	547	56
Other conditions (DMO, RVO or mCNV)	537	78	391	35	146	43